Larimar Therapeutics Inc. (NASDAQ: LRMR)
$9.98
-0.6000 ( -5.67% ) 172.2K
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
Market Data
Open
$9.98
Previous close
$10.58
Volume
172.2K
Market cap
$639.93M
Day range
$9.88 - $10.57
52 week range
$2.18 - $13.68
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Feb 15, 2024 |
8-k | 8K-related | 12 | Feb 14, 2024 |
8-k | 8K-related | 83 | Feb 12, 2024 |
4 | Insider transactions | 1 | Jan 19, 2024 |
4 | Insider transactions | 1 | Jan 19, 2024 |
4 | Insider transactions | 1 | Jan 19, 2024 |
4 | Insider transactions | 1 | Jan 19, 2024 |
4 | Insider transactions | 1 | Dec 08, 2023 |
10-q | Quarterly Reports | 53 | Nov 14, 2023 |
8-k | 8K-related | 60 | Nov 14, 2023 |